The primary therapeutic role of Неотон (Phosphocreatine) is to provide supportive metabolic support and protective benefit across specific, high-stress cardiovascular contexts. It is used for managing symptoms that create noticeable physiological strain on the heart.

Acute Cardiac Ischemic Events

This domain is commonly used across conditions characterized by periods of heightened symptoms, such as acute myocardial infarction and severe ischemia. The substance may assist with the treatment of various cardiac disorders. The medication supports the heart muscle by easing the impact of ischemic damage and helps manage the symptoms related to heightened physiological activity (abnormal rhythm), which may assist with the patient's well-being during the acute phase of a coronary event. Indications may include conditions associated with acute or disruptive episodes, such as acute myocardial infarction, myocardial ischemia, and situations requiring supportive symptomatic assistance.

Myocardial Protection During Cardiac Surgery

Неотон is applied in clinical settings that involve acute or unstable symptom patterns related to surgical stress. Its use in this context supports the heart during the heightened physiological stress of surgery, including use relevant in contexts involving heightened systemic burden during surgical procedures, and may help with managing symptoms related to systemic imbalance (like rhythm abnormalities) in the recovery phase. This supportive benefit is considered relevant when tissues are under temporary functional strain.

“The medication supports patients during episodes of heightened discomfort when the heart muscle is expected to undergo a period of significant physiological stress.”

Functional Support in Chronic Heart Failure

This medicine is used in areas where short-term symptom management is appropriate as an adjunctive treatment for patients with established chronic heart failure, particularly in situations where symptoms interfere with daily functioning. It offers symptomatic relief that may assist with maintaining functional stability in the heart and supports general well-being during symptomatic phases, which may help with functional capability.

---

Quick Fact: Relief for Functional Strain Неотон is commonly used for conditions involving episodic or fluctuating manifestations of heart strain, specifically to support the heart muscle during periods of acute oxygen deprivation or functional decline, assisting with maintaining functional stability.

Regulatory References

1. NIH MeSH overview

The eligibility profile for Неотон (Phosphocreatine) is defined by strict regulatory criteria governing its use in the adult population. Official documentation establishes clear exclusions and limitations based on specific clinical states, age, and physiological status.

Populations for Whom Use is Contraindicated

Use of Неотон is absolutely contraindicated in patients with a known hypersensitivity to phosphocreatine or any of the product's components. A further absolute restriction applies to patients experiencing conditions of profound cardiovascular instability, specifically severe arterial hypotension (low blood pressure) or cardiogenic shock. Use is also prohibited in patients with chronic kidney failure or severe renal impairment due to the drug's metabolic and excretory profile.

Populations Requiring Restriction or Special Status

The medicine is not established or not recommended for use in the pediatric population (children and adolescents under 18 years) due to insufficient regulatory data on safety and efficacy in these age groups. Similarly, official labeling does not recommend use during pregnancy or lactation unless the use is deemed essential and the benefit outweighs potential risks, based on a lack of adequate safety studies. Caution is also advised in patients with existing cardiac conduction abnormalities like Bradycardia or Atrioventricular (AV) Block.

Interactions with other medicines and products

Regulatory documents define the interaction profile of Phosphocreatine (Неотон) primarily by its potential for pharmacodynamic reinforcement with specific inotropic agents. This profile, focusing on additive effects rather than metabolic alterations, governs the required considerations for co-administration in the clinical setting.

---

Documented Pharmacodynamic Interactions

Co-administration with certain medicinal products that increase the force of cardiac contraction may lead to a clinically significant additive effect. The official prescribing information documents this specific interaction type.

Interacting Medicinal Product(s)	Official Interaction Outcome (Regulatory Description)
Dopamine	Co-administration may result in an increase in the inotropic effect of Dopamine.
Dobutamine	Co-administration may result in an increase in the inotropic effect of Dobutamine.

---

Absence of Documented Pharmacokinetic Interactions

Official regulatory labeling does not include data for significant pharmacokinetic interactions involving the clearance or exposure of phosphocreatine. This is defined by the absence of documented interactions related to major Cytochrome P450 enzymes or specific drug transporters (e.g., P-gp).

Other Interaction Considerations

There are no explicitly documented interaction restrictions in the regulatory information regarding the co-administration of phosphocreatine with food, alcohol, herbal products, or dietary supplements. Furthermore, the labeling does not list mandatory timing separation requirements for co-administered medicines, nor does it specify population-dependent changes in interaction severity (e.g., in elderly or renally impaired patients).

How Неотон Works: The Core Mechanisms

---

Intracellular Energy Buffering and ATP Stabilization

Неотон (Phosphocreatine) acts as a high-energy phosphate donor, rapidly replenishing ATP (adenosine triphosphate) via the creatine kinase system in metabolically stressed cells, particularly in the myocardium. This influences the regulation of energy-dependent processes, leading to the maintenance of cellular function during periods of oxygen deprivation.

---

Myocardial Membrane and Ion Homeostasis

This mechanism engages processes that stabilize the cell membrane structure, limiting the accumulation of toxic byproducts and preventing the uncontrolled influx of ions, such as calcium ( Ca^2+), during ischemia. By limiting this destabilization, the drug facilitates a shift toward an ionically balanced state within targeted pathways and modulates the processes affecting the cell’s electrophysiological integrity.

---

Modulation of Ischemic-Reperfusion Injury Cascades

Неотон modifies early molecular steps involved in the damage that occurs when blood flow returns to oxygen-deprived tissue (reperfusion). It influences pathways related to oxidative stress and modulates endothelial cell pathway activity, which reduces the magnitude of the downstream impact of excessive mediator activity and secondary tissue damage.

How to Use Neoton (Phosphocreatine Disodium Salt) — Administration Overview

This section describes the standardized usage for Neoton (Phosphocreatine Disodium Salt). The method, dosage, and rate of administration are characterized as follows:

---

Administration Scope

Instruction Component	Labeled Instruction
Route of Administration	Intravenous (IV) Infusion or IV Injection. Also used as an additive in Cardioplegic Solution during cardiac surgery.
Dosing Schedule	Acute/Loading Dose: A single, initial dose of 8 g administered via slow IV infusion. Maintenance Dose: 2 g to 4 g administered daily via IV infusion for subsequent days.
Preparation Requirements	The powdered substance must be reconstituted (mixed with a solvent like Water for Injections) and then diluted for infusion by a healthcare professional.
Timing in Relation to Meals	Administration is independent of meals (can be given with or without food).
Special Procedural Conditions	The rate of administration must be controlled: the 8 g dose requires infusion over a minimum of 90 minutes. A 2 g dose requires a minimum infusion time of 30 minutes.

---

Procedural Structure

The administration sequence involves a specific process: the initial dose is prepared, diluted, and infused slowly to achieve the loading effect. This is followed by daily maintenance doses, also administered intravenously at a controlled rate. For surgical application, 10 g is added to one liter of standard cardioplegic solution. These steps represent the standardized approach for using the medicine.

Research Evidence / Overview of Studies for Неотон

This section provides a transparent overview of the research that has been conducted on Неотон (Phosphocreatine). It describes the types of studies available and what they monitored, without making claims about specific patient outcomes or providing medical advice. The purpose is to share what the current research landscape looks like and what aspects remain uncertain.

---

Evidence for Use in Acute Cardiac Ischemic Events

Research examined Неотон’s use in patients with conditions studied in trials, such as those experiencing acute cardiac events. Studies conducted during periods of increased symptom activity, like an acute heart attack, focused on adult patients who were also receiving standard care.

Investigators studied outcomes related to physiological stress, including heart rhythm changes (arrhythmias) and the levels of biomarkers associated with heart muscle injury. Studies reported measurements of these injury biomarkers during the study period. However, findings were mixed and varied across the published studies, and the observed outcomes were short-term and based on modest populations.

---

Evidence for Myocardial Protection During Heart Surgery

Research explored Неотон’s application in patients undergoing heart surgery. These studies included randomized controlled trials and clinical studies, focusing on both adult and pediatric patients undergoing complex procedures that place significant stress on the heart.

Investigators monitored outcomes related to physiological strain, such as the requirement for post-surgical circulatory support and the immediate recovery of heart rhythm. Studies also monitored markers of heart muscle injury. Findings showed patterns related to these metrics, but the results varied across the combined research. The current data is mostly confined to the intraoperative and immediate postoperative period. Therefore, long-term effects are not fully established.

---

What is Still Uncertain About the Research for Неотон

Reviewing the research highlights several areas where more information is needed. While existing studies contribute to understanding symptom patterns and physiological changes, certainty remains low in several key areas.

One main uncertainty lies in the duration of the effect, as long-term effects are not fully established. Another is the lack of large-scale, universally consistent trials for all indications; for example, evidence quality varies across studies, especially for chronic heart failure ( CHF) support. The research highlights what is known regarding short-term support during acute physiological stress but is limited in its ability to provide comprehensive, long-term data on survival or functional status for most patients.

Key Studies & References

1. Phosphocreatine - MeSH (National Library of Medicine controlled vocabulary for definition and uses)

Common questions about Неотон (FAQ)

Q: How long after I finish the infusion can I safely drive a car or operate machinery?

Regulatory documents generally state that formal studies assessing the medicine's direct impact on the ability to drive or operate machinery have not been performed. If the medicine causes side effects, such as dizziness, blurred vision, or light-headedness, patients experiencing these effects are generally advised to avoid driving or operating machinery until symptoms have completely resolved. Specific individual guidance is best determined by a healthcare provider.

Q: What is the specific maximum rate of infusion for the 8 g dose?

The official administration instructions specify a minimum infusion time, which establishes the maximum speed at which the medicine is intended to be given. For example, the prescribed 8 g dose is intended to be administered via slow infusion over a period of no less than 90 minutes (one hour and thirty minutes). Adherence to the minimum time ensures the infusion rate remains within the established maximum limits.

Q: Is it okay to mix Neoton with other drugs in the same IV bag?

The official product information lists specific chemical and physical incompatibilities with other substances. This information dictates whether the medicine can be physically mixed or co-administered with other treatments in the same IV bag or syringe. Healthcare professionals determine the compatibility of mixing based on a review of the official product labeling.

Q: What should I do if I miss my scheduled maintenance dose?

Guidance for handling a missed dose is typically included in the official patient information for the medicine. Patients are generally advised to speak with a healthcare professional regarding any missed doses. It is generally advised not to administer a double dose to compensate for the missed one, but rather to continue with the next scheduled dose as planned.

Q: How does Неотон affect blood pressure in general?

The regulatory text notes that the medicine is contraindicated (advised against) for use in patients who have severe arterial hypotension, which is extremely low blood pressure. While this highlights a known risk related to blood pressure in high-risk patients, the official product information does not explicitly describe its common effect (e.g., if it typically raises or lowers blood pressure) in patients with normal blood pressure.

Q: What do I do if I am given too much of this medicine (overdose)?

Official regulatory documentation provides specific details on how an overdose should be managed. In the event of an overdose, official guidance directs that the infusion should be discontinued. Healthcare professionals then provide treatment based on the specific symptoms that are observed, typically involving symptomatic and supportive care.

Q: Are there any known issues with Neoton use in the elderly (over 65)?

Official regulatory documents typically address the need for specific dose adjustments or special precautions in patient groups like the elderly. If no special dose adjustment or precaution is explicitly mentioned in the official labeling, the use of the medicine in older adults is considered similar to that in other adults, provided they do not have severe underlying conditions such as kidney or heart failure.

Q: If I have an allergic reaction to Neoton, what ingredients could be the cause?

All potential causes of an allergic reaction are listed in the official product information under the list of ingredients. This list includes both the active substance, Phosphocreatine, and all of the inactive ingredients, known as excipients. If symptoms of a severe allergic reaction occur, such as difficulty breathing or swelling, prompt medical attention is necessary.

Official Storage and Disposal Guidelines for Неотон

Official regulatory guidelines strictly define the conditions for storing and disposing of Неотон (Phosphocreatine sodium) to maintain product quality and safety.

Storage of Unopened Vials

Condition	Requirement
Temperature	Store at a temperature not exceeding 25 C (controlled room temperature).
Protection	Keep the lyophilized powder in its original container to protect it from light.
Safety	The medicine must be kept out of the sight and reach of children.

Stability and Disposal Rules

Once the powder is reconstituted into a solution for infusion, the product must be used immediately due to rapid degradation. Any remaining or expired Неотон must be disposed of in accordance with local pharmaceutical waste regulations. It is strictly prohibited to dispose of the product by throwing it into household trash or flushing it into wastewater.